Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PROKIDNEY CORP.

Get SEC filing alerts via email and in your feed for PROKIDNEY CORP.

PROK

PROKIDNEY CORP.

About PROKIDNEY CORP.

ProKidney Corp. is a clinical-stage biotechnology company developing autologous cell therapies to treat chronic kidney disease (CKD). Its lead product, rilparencel, uses patient-derived kidney cells to preserve kidney function and delay progression to end-stage renal disease. The company focuses on regenerative medicine, clinical trials, and manufacturing personalized therapies, targeting markets with high unmet needs in CKD management and aiming for regulatory approval and commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PROKIDNEY CORP.

1
1
PROKIDNEY CORP. ProKidney Reports Decrease in Revenue and Increase in Operating Expenses for Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
PROKIDNEY CORP. ProKidney Corp. Reports Fiscal Year 2025 Results and Focus on Rilparencel Development

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
PROKIDNEY CORP. ProKidney Reports $217,000 Revenue in Q3 2025, Net Loss of $35.8 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PROKIDNEY CORP. ProKidney Reports $221,000 Revenue in Q2 2025, Continues to Operate at a Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PROKIDNEY CORP. ProKidney Reports $230,000 Revenue in Q1 2025, Net Loss Increases to $37.9 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PROKIDNEY CORP. ProKidney Reports $163.3 Million Net Loss for 2024, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PROKIDNEY CORP. ProKidney Corp. Reports Financial Results, Cash and Cash Equivalents Increase to $108.1 Million

Via official filing (AI summary) | over 1 year ago | 0 comments